Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Dapagliflozin 2.5mg + Glimepiride
Total, all-cause mortality	Dapagliflozin 5mg + Glimepiride
Total, all-cause mortality	Dapagliflozin 10mg + Glimepiride
Total, all-cause mortality	Placebo + Glimepiride
Total, other adverse events	Dapagliflozin 2.5mg + Glimepiride	22	154
Total, other adverse events	Dapagliflozin 5mg + Glimepiride	19	145
Total, other adverse events	Dapagliflozin 10mg + Glimepiride	18	151
Total, other adverse events	Placebo + Glimepiride	15	146
Total, serious adverse events	Dapagliflozin 2.5mg + Glimepiride	11	154
Total, serious adverse events	Dapagliflozin 5mg + Glimepiride	10	145
Total, serious adverse events	Dapagliflozin 10mg + Glimepiride	9	151
Total, serious adverse events	Placebo + Glimepiride	7	146

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00680745/event-totals